Phase I Study of Induction Cisplatin, Docetaxel and Nintedanib for Stage IB-IIIA Non-small Cell Lung Cancers Amenable for Surgical Resection
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Nintedanib (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Aug 2017 Planned End Date changed from 1 Jun 2020 to 1 Apr 2020.
- 02 Aug 2017 Planned primary completion date changed from 1 Jun 2020 to 1 Apr 2020.
- 08 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.